奥地利老年男性下尿路症状的管理

Management of lower urinary tract symptoms of elderly men in Austria.

作者信息

Madersbacher S, Haidinger G, Struhal G

机构信息

Department of Urology, University of Vienna, Austria.

出版信息

Eur Urol. 2001 Feb;39(2):145-50. doi: 10.1159/000052429.

DOI:10.1159/000052429

PMID:11223673

Abstract

OBJECTIVES

The aim of this nation-wide study was to determine the current management of elderly men with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) and benign prostatic enlargement (BPE) in Austria, and to assess changes over a 4-year study period from 1995 to 1998.

METHODS

The annual figures of prostatectomies performed in Austria from 1995 to 1998 were collected from the Austrian Institute for Health Affairs. Sales figures for finasteride, alpha(1)-receptor blockers and plant extracts were obtained from IMS market sales and Austrian regional compulsory insurance companies. These data were correlated with the number of males living in Austria during the study period and to the estimated numbers of elderly men with moderate and severe LUTS in this country.

RESULTS

The annual number of transurethral resections of the prostate (TURPs) decreased from 6,302 in 1995 to 5,297 in 1998 (-16%), and the number of open prostatectomies from 506 to 469 (-7%). Extrapolation of these data to 100,000 men aged > or = 55 years revealed that 0.76% underwent TURP in 1995, this figure decreased to 0.59% in 1998. Market sales of alpha(1)-receptor blockers increased by 497% during the study period and those of finasteride by 1.6%, while plant extract market sales declined by 18.2%. In 1998, plant extracts comprised 43.3% of the total BPH market, alpha(1)-receptor blockers 41.5% and finasteride 15.2%.

CONCLUSIONS

During the years 1995-1998, significant changes in medical and surgical BPH therapy were observed in Austria. These data provide the basis for a comparison to the situation in other countries and serve as a baseline investigation for future studies in this country.

摘要

目的

这项全国性研究旨在确定奥地利对因良性前列腺增生（BPH）和良性前列腺肿大（BPE）导致下尿路症状（LUTS）的老年男性的当前治疗情况，并评估1995年至1998年这4年研究期间的变化。

方法

从奥地利卫生事务研究所收集1995年至1998年奥地利每年进行前列腺切除术的数字。非那雄胺、α1受体阻滞剂和植物提取物的销售数字从IMS市场销售数据和奥地利地区强制保险公司获得。这些数据与研究期间奥地利男性的数量以及该国中度和重度LUTS老年男性的估计数量相关。

结果

经尿道前列腺切除术（TURP）的年手术量从1995年的6302例降至1998年的5297例（-16%），开放性前列腺切除术的数量从506例降至469例（-7%）。将这些数据推算至100,000名年龄≥55岁的男性，结果显示1995年接受TURP的比例为0.76%，1998年降至0.59%。在研究期间，α1受体阻滞剂的市场销售额增长了497%，非那雄胺增长了1.6%，而植物提取物的市场销售额下降了18.2%。1998年，植物提取物占BPH市场总量的43.3%，α1受体阻滞剂占41.5%，非那雄胺占15.2%。